2. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

fibrosis pathway

" in MedChemExpress (MCE) Product Catalog:

156

Inhibitors & Agonists

3

Screening Libraries

14

Peptides

2

Inhibitory Antibodies

48

Natural
Products

10

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116084
    Trimethylamine N-oxide
    10+ Cited Publications

    		 Drug Metabolite NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) TGF-beta/Smad Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway .
    Trimethylamine N-oxide
  • HY-B0252
    Hydrochlorothiazide
    5+ Cited Publications

    HCTZ

    		 TGF-beta/Smad Potassium Channel Cardiovascular Disease Metabolic Disease Cancer
    Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazide
  • HY-N2329
    Piperlongumine
    10+ Cited Publications

    Piplartine

    		 ERK Reactive Oxygen Species (ROS) Autophagy Apoptosis Bacterial Ferroptosis Infection Cardiovascular Disease Cancer
    Piperlongumine is a alkaloid , possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities . Piperlongumine induces ROS, and induces apoptosis in cancer cell lines . Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome .
    Piperlongumine
  • HY-112654
    GCN2iB
    55+ Cited Publications

    		 Eukaryotic Initiation Factor (eIF) Glutathione Peroxidase Cardiovascular Disease Metabolic Disease Cancer
    GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy .
    GCN2iB
  • HY-N0512
    Loganin
    5 Publications Verification

    Loganoside

    		 Reactive Oxygen Species (ROS) TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    Loganin is a type of iridoid glycoside compound that possesses anti-inflammatory, antioxidant, and antitumor properties, and offers protective effects against acute lung injury and pulmonary fibrosis. Loganin exerts its protective effects against LPS (HY-D1056)-mediated inflammation and oxidative stress by upregulating the Nrf2/HO-1 signaling pathway, and it reduces neuroinflammation caused by spinal cord injury (SCI) .
    Loganin
  • HY-158426
    2-APQC
    1 Publications Verification

    		 Sirtuin Cardiovascular Disease
    2-APQC is an orally active and selective agonist of Sirtuin-3 (SIRT3) (Kd=2.756 μM), antagonizes Isoproterenol/ISO (HY-B0468)-induced cytotoxicity. 2-APQC activates the SIRT3-PYCR1 axis to enhance mitochondrial proline metabolism and inhibit the ROS-p38MAPK pathway by inhibiting signaling pathways such as mTOR-p70S6K, JNK, and TGF-β/Smad3. 2-APQC also activates the AMPK-Parkin axis to alleviate myocardial hypertrophy and fibrosis and protect cardiac function. 2-APQC can be used in the study of heart failure .
    2-APQC
  • HY-100113
    Buloxibutid
    5 Publications Verification

    AT2 receptor agonist C21

    		 Angiotensin Receptor p38 MAPK TGF-beta/Smad TGF-β Receptor MMP Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis .
    Buloxibutid
  • HY-N0202
    Atractylenolide II
    3 Publications Verification

    Asterolide

    		 ERK Apoptosis p38 MAPK Akt Src STAT Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity .
    Atractylenolide II
  • HY-W008947
    SEW​2871
    5+ Cited Publications

    		 LPL Receptor ERK Akt Neurological Disease Metabolic Disease Inflammation/Immunology
    SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .
    SEW​2871
  • HY-128483
    Fusaric acid

    		TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
    Fusaric acid
  • HY-108915
    Trimethylamine N-oxide dihydrate
    10+ Cited Publications

    		 NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) TGF-beta/Smad Endogenous Metabolite Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Trimethylamine N-oxide dihydrate is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide dihydrate induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide dihydrate also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway .
    Trimethylamine N-oxide dihydrate
  • HY-116084S
    Trimethylamine N-oxide-d9
    1 Publications Verification

    		 NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) TGF-beta/Smad Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Trimethylamine N-oxide-d9 is the deuterium labeled Trimethylamine N-oxide. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway .
    Trimethylamine N-oxide-d9
  • HY-P10899
    ETTAC-2

    		PROTACs TGF-beta/Smad Endocrinology
    ETTAC-2 is a LRG1 PROTAC degrader, degrading LRG1 via the ubiquitin-proteasome pathway with a DC50 value of 8.38 μM. ETTAC-2 penetrates damaged renal cells to reduce the extracellular secretion of LRG1. ETTAC-2 effectively inhibits the TGF-β-Smad3 signaling pathway and diminishes the secretion of fibrosis-associated extracellular matrix proteins. ETTAC-2 degrades LRG1 within fibrotic kidneys and the efficacy in inhibiting the TGF-β-Smad3 pathway both in vitro and vivo. ETTAC-2 can be used for renal fibrosis research .
    ETTAC-2
  • HY-N6985
    Baccatin III
    2 Publications Verification

    		 Others Cancer
    Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment .
    Baccatin III
  • HY-112671
    CDDO-dhTFEA

    RTA dh404

    		 Keap1-Nrf2 NF-κB Apoptosis Cardiovascular Disease Inflammation/Immunology
    CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB . CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats .
    CDDO-dhTFEA
  • HY-N0671
    Rhapontin
    2 Publications Verification

    Rhaponiticin

    		 Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin
  • HY-N2413
    Gomisin D

    		PDGFR UGT Reactive Oxygen Species (ROS) Apoptosis Tyrosinase p38 MAPK Akt ERK COX Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology
    Gomisin D is an orally active lignan that binds to PDGFRβ with a Kd of 10 μM. By targeting PDGFRβ to regulate signaling pathways, Gomisin D inhibits the activation and proliferation of hepatic stellate cells and promotes their apoptosis, thereby ameliorating hepatic fibrosis. Gomisin D exhibits multiple activities such as photoprotection, antimelanogenesis, antioxidant effects, and hypoglycemic activity. Gomisin D can be used in studies related to diabetes, Alzheimer's disease, and hepatic fibrosis .
    Gomisin D
  • HY-N0546
    Ligustroflavone
    2 Publications Verification

    Nuezhenoside

    		 CaSR RIP kinase Mixed Lineage Kinase TGF-beta/Smad Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
    Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis .
    Ligustroflavone
  • HY-111432
    CCG-232601

    		Ras Others
    CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma .
    CCG-232601
  • HY-121750
    CCG-222740
    1 Publications Verification

    		 Ras ROCK Cancer
    CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor . CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis .
    CCG-222740
  • HY-N0617
    Sanggenon C
    2 Publications Verification

    		 Phosphatase ERK NF-κB Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Sanggenon C, a flavonoid, exerts protective effects against cardiac hypertrophy and fibrosis via suppression of the calcineurin/NFAT2 pathway. Sanggenon C inhibits mitochondrial fission to induce apoptosis by blocking the ERK signaling pathway. Sanggenon C inhibits inducible nitric oxide synthase expression in RAW264.7 cells, and TNF-α-stimulated cell adhesion and VCAM-1 expression, by suppressing NF-κB activity. Sanggenon C possesses antioxidant, anti-inflammatory and antitumor activities .
    Sanggenon C
  • HY-123581
    Quinocetone
    1 Publications Verification

    		 Antibiotic Bacterial ATF6 DAPK Autophagy NF-κB NO Synthase Apoptosis Reactive Oxygen Species (ROS) Keap1-Nrf2 Heme Oxygenase (HO) Infection Inflammation/Immunology
    Quinocetone is an orally active animal feed additive used to increase the meat production of livestock and poultry. Quinocetone exhibits antibacterial activity against a variety of pathogenic microorganisms. Quinocetone exhibits tissue-specific (liver, lymphocyte) toxicity. Quinocetone induces autophagy in cells through the ATF6/DAPK1 pathway. Quinocetone activates the NF-κB and iNOS pathways, leading to cell apoptosis, hepatocyte vacuolar degeneration and fibrosis. Quinocetone can inhibit Nrf2/HO-1 and induce the generation of reactive oxygen species (ROS), leading to oxidative stress and DNA damage .
    Quinocetone
  • HY-P10728
    B7-33

    		RXFP Receptor ERK Cardiovascular Disease Inflammation/Immunology
    B7-33 is a single-chain relaxin mimetic and a selective relaxin receptor 1 (RXFP1) agonist. B7-33 phosphorylates ERK1/2 without inducing activation of the cAMP signaling pathway. B7-33 exhibits anti-fibrotic and cardioprotective activities. B7-33 can be used in the research of vascular diseases such as cardiomyopathy, myocardial infarction and fibrosis .
    B7-33
  • HY-N0247
    Saikosaponin B1
    2 Publications Verification

    		 Hedgehog Smo STAT Interleukin Related TNF Receptor Inflammation/Immunology Cancer
    Saikosaponin B1 is a bioactive constituent of Radix Bupleuri. Saikosaponin B1 is an agonist of the 5-HT2C receptor with an EC50 of 147.41 μM. Saikosaponin B1 inhibits the Hedgehog (Hh) signaling pathway by targeting the transmembrane protein SMO. Sailosaponin B1 can reduce liver fibrosis. Saikosaponin B1 has anti-cancer activities thus can be studies in research for cancers such as Medulloblastoma (MB) .
    Saikosaponin B1
  • HY-N2013
    Aristolactam I
    1 Publications Verification

    Aristololactam; Aristolactam

    		 Drug Metabolite Aquaporin Cadherin TGF-beta/Smad Endocrinology Cancer
    Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis .
    Aristolactam I
  • HY-D0961
    Gallocyanine chloride

    		Fluorescent Dye Wnt β-catenin Neurological Disease Inflammation/Immunology Cancer
    Gallocyanine chloride is a synthetic blue dyestuff that can be used as a potential agent for the research of Alzheimer's disease and related neurodegenerative tauopathies. Gallocyanine chloride inhibits DKK1/LRP6 interaction (IC50=6.38 μM), activates Wnt signaling pathway, and causes β-catenin accumulation. Gallocyanine chloride exhibits anti-metastasis, anti-inflammatory and anti-fibrosis activities. Gallocyanine chloride can be used as a fluorescent probe for detection of superoxide anion radicals .
    Gallocyanine chloride
  • HY-N0912
    Rehmannioside D
    1 Publications Verification

    		 Sirtuin Apoptosis MDM-2/p53 Reactive Oxygen Species (ROS) Bcl-2 Family Caspase Metabolic Disease Inflammation/Immunology
    Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis .
    Rehmannioside D
  • HY-N7400
    Phaseoloidin

    		NOD-like Receptor (NLR) Caspase Insecticide Inflammation/Immunology
    Phaseoloidin is an orally active multi-target inhibitor. Phaseoloidin inhibits the activation of the NLRP3 inflammasome and blocks the caspase-11-GSDMD pyroptosis axis. Phaseoloidin reduces the expression of collagen-degrading enzymes to maintain the integrity of cartilage matrix. Phaseoloidin activates the AMPK/mTOR pathway to enhance autophagic function. Phaseoloidin exerts adverse effects on the growth and development of Manduca sexta and Spodoptera littoralis larvae, inhibits larval growth, and thereby helps Nicotiana attenuata defend against lepidopteran herbivorous insects. Phaseoloidin is applicable to research related to acute gouty arthritis and pulmonary fibrosis .
    Phaseoloidin
  • HY-121246
    Fluorofenidone
    1 Publications Verification

    AKF-PD

    		 ACSL Family NF-κB ERK TGF-beta/Smad Inflammation/Immunology Cancer
    Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC) .
    Fluorofenidone
  • HY-N6983
    Licoricesaponin G2

    		TNF Receptor PI3K Akt mTOR Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Licoricesaponin G2 is an orally active component found in Licorice. Licoricesaponin G2 significantly ameliorates Bleomycin (HY-108345)-induced pulmonary fibrosis by inhibiting the TNF-α signaling pathway, reducing epithelial-mesenchymal transition, and decreasing extracellular matrix deposition. Licoricesaponin G2 inhibits cancer cells proliferation, migration, inhibits PI3K/AKT/mTOR signaling pathway and increases ROS production. Licoricesaponin G2 can be used for the research of lung cancer and pulmonary fibrosis .
    Licoricesaponin G2
  • HY-P991219
    Anti-IL11RA Antibody (X209)

    EnX209

    		 Interleukin Related ERK MMP Inflammation/Immunology
    Anti-IL11RA Antibody (X209) (EnX209) is a human-derived IgG4, κ-type antibody inhibitor targeting IL11RA, with a KD of 6 nM. Anti-IL11RA Antibody (X209) blocks the IL11RA signaling pathway, inhibits ERK-dependent activation, and reduces the activation level of ERK1/2. Anti-IL11RA Antibody (X209) exerts a protective effect against fibrosis. Anti-IL11RA Antibody (X209) is applicable to studies related to liver fibrosis, cardiac fibrosis and other related conditions. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .
    Anti-IL11RA Antibody (X209)
  • HY-N0008
    Orcinol glucoside

    		Wnt p38 MAPK mTOR Keap1-Nrf2 TGF-β Receptor Neurological Disease Metabolic Disease
    Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and p70S6K, and inhibits the enzymatic activity of HAS2 as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases .
    Orcinol glucoside
  • HY-168906
    BI-113823

    		Bradykinin Receptor PI3K Akt TNF Receptor ERK Neurological Disease Inflammation/Immunology
    BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension .
    BI-113823
  • HY-18102
    GLPG0492
    5+ Cited Publications

    		 Androgen Receptor Neurological Disease
    GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .
    GLPG0492
  • HY-W018197
    2-Phenylacetamide

    		Endogenous Metabolite p38 MAPK Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology Cancer
    2-Phenylacetamide is a estrogen-like compound that can be isolated from Lepidium apetalum seeds. 2-Phenylacetamide inhibits p38 MAPK signaling pathway, exhibits anti-inflammatory, antioxidant, anti-hypertensive, and anti-fibrosis effects. 2-Phenylacetamide is orally active .
    2-Phenylacetamide
  • HY-112247
    SR 16832

    		PPAR TGF-beta/Smad Metabolic Disease Inflammation/Immunology
    SR 16832 is a dual-site covalent, orthosteric and allosteric PPARγ antagonist. SR 16832 activates the TGF-β signaling pathway and upregulates the expression of Vimentin and Fibronectin (Fibronectin). SR 16832 is toxic to bronchial epithelium. SR 16832 can be used in research related to type 2 diabetes and pulmonary fibrosis .
    SR 16832
  • HY-130687A
    Psicose

    DL-Psicose

    		 PI3K mTOR Akt IGF-1R Inflammation/Immunology
    Psicose is a natural and low-calorie sweetener. Psicose can activate the PI3K/Akt/mTOR pathway to promote muscle synthesis. Psicose can upregulate IGF-1 and downregulate Myostatin. Psicose regulates mitochondrial function by increasing G6P activity. Psicose enhances antioxidant enzyme activity and reduces oxidative stress markers. Psicose reduces plasma triglycerides and total cholesterol. Psicose can improve muscle fiber size and reduce fibrosis. Psicose can be used for research on sarcopenia .
    Psicose
  • HY-108464A
    Phenamil methanesulfonate

    		Sodium Channel TRP Channel Metabolic Disease Inflammation/Immunology
    Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC50 of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca 2+ transport with an IC50 of 140 nM in a Ca 2+ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .
    Phenamil methanesulfonate
  • HY-128439
    BT173

    		DYRK Cancer
    BT173 is a potent homeodomain interacting protein kinase 2 (HIPK2) inhibitor. BT173 binds to HIPK2 and does not inhibit HIPK2 kinase activity but rather, interfered allosterically with the ability of HIPK2 to associate with Smad3. BT173 attenuates renal fibrosis through suppression of the TGF-β1/Smad3 pathway. BT173 can be studied in research for kidney diseases such as renal fibrosis .
    BT173
  • HY-B0252S1
    Hydrochlorothiazid-13C,d2

    HCTZ-13C,d2

    		 Isotope-Labeled Compounds TGF-beta/Smad Potassium Channel Cardiovascular Disease Metabolic Disease
    Hydrochlorothiazid- 13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazid-13C,d2
  • HY-151483
    TK-129

    		Wnt Histone Demethylase Cardiovascular Disease
    TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC50=44 nM). TK-129 exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease .
    TK-129
  • HY-W005379
    DGM

    		TGF-beta/Smad Inflammation/Immunology
    DGM is an inhibitor of the TGF-β1/Smad signaling pathway with significant antifibrotic effects. DGM inhibits the epithelial-mesenchymal transition (EMT) process in alveolar epithelial cells and slows the progression of pulmonary fibrosis in vivo by reducing lung inflammation, improving lung function, and decreasing extracellular matrix (ECM) remodeling. DGM can be used in research on idiopathic pulmonary fibrosis (IPF) and EMT-related diseases .
    DGM
  • HY-178821
    ROCK2-IN-12

    		ROCK TGF-beta/Smad STAT Inflammation/Immunology
    ROCK2-IN-12 (Compound A25) is a selective ROCK2 inhibitor with an IC50 of 7.0  nM for ROCK2 over ROCK1. ROCK2-IN-12 has potent antifibrotic effects via the TGF-β/Smad and ROCK2/STAT3 signaling pathways. ROCK2-IN-12 significantly reduces collagen deposition and reverses fibrotic progression in Bleomycin (HY-108345)-induced pulmonary fibrosis (PF) mouse models. ROCK2-IN-12 can be used for lung diseases like pulmonary fibrosis research .
    ROCK2-IN-12
  • HY-B0252R
    Hydrochlorothiazide (Standard)
    5+ Cited Publications

    HCTZ (Standard)

    		 Reference Standards TGF-beta/Smad Potassium Channel Cardiovascular Disease Metabolic Disease Cancer
    Hydrochlorothiazide (Standard) is the analytical standard of Hydrochlorothiazide. This product is intended for research and analytical applications. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazide (Standard)
  • HY-156065
    S217879

    		Keap1-Nrf2 Reactive Oxygen Species (ROS) Interleukin Related Metabolic Disease
    S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis .
    S217879
  • HY-B0252S
    Hydrochlorothiazid-d2

    HCTZ-d2

    		 TGF-beta/Smad Potassium Channel Cardiovascular Disease Metabolic Disease
    Hydrochlorothiazid-d2 is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazid-d2
  • HY-171878
    BI-4659

    		TGF-β Receptor PDGFR TGF-beta/Smad Inflammation/Immunology Cancer
    BI-4659 is a TGFβRI and PDGFRα inhibitor with IC50 values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and PDGFRα, blocks the downstream TGFβRI signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1. BI-4659 is applicable to research related to pulmonary fibrosis, cancer, and renal ischemia-reperfusion injury .
    BI-4659
  • HY-116084S1
    Trimethylamine-N-oxide-13C3

    		Isotope-Labeled Compounds NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) TGF-beta/Smad Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Trimethylamine-N-oxide- 13C3 is the 13C-labeled Trimethylamine N-oxide. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway .
    Trimethylamine-N-oxide-13C3
  • HY-179133
    HDB-1

    		P2Y Receptor PKA Raf MEK ERK Inflammation/Immunology
    HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC50 of 26 pM. HDB-1 shows no significant inhibition on P2Y1R, P2Y2R, P2Y4R, P2Y6R, and P2Y12R. HDB-1 blocks the activation of hepatic stellate cells (HSC) by inhibiting the PKA/Raf1/MEK/ERK signaling pathway mediated by P2Y14R, thereby alleviating the core pathological process of liver fibrosis. HDB-1 can be used for the study of liver fibrosis .
    HDB-1
  • HY-B0252S3
    Hydrochlorothiazide-15N2,13C,d2

    HCTZ-15N2,13C,d2

    		 Potassium Channel TGF-beta/Smad Isotope-Labeled Compounds Cardiovascular Disease Metabolic Disease Cancer
    Hydrochlorothiazide- 15N2, 13C,d2 is 15N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .
    Hydrochlorothiazide-15N2,13C,d2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: